BRIDGEWATER, N.J., Nov. 16, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Aripiprazole Tablets (2.5mg, 5mg, 10mg, 15mg, 20mg, 30mg), a bioequivalent generic version of Abilify®1, into the US market.
Aripiprazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the United States Food & Drug Administration.
About Ajanta Pharma
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.
For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
1 Abilify® is a registered trademark of Otsuka Pharmaceutical Co.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-aripiprazole-tablets-300364320.html
SOURCE Ajanta Pharma USA Inc.